Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia
Purpose: Most randomized clinical trials evaluating second generation tyrosine kinase inhibitors (TKI) for the first-line treatment of Chronic Myeloid Leukemia used as comparator the ‘standard’ dose of 400 mg imatinib daily. Several studies showed higher rates of major molecular remission (MMR) at 1...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
08 March 2017
|
| In: |
Journal of cancer research and clinical oncology
Year: 2017, Jahrgang: 143, Heft: 7, Pages: 1311-1318 |
| ISSN: | 1432-1335 |
| DOI: | 10.1007/s00432-017-2385-7 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00432-017-2385-7 Verlag, Volltext: https://link-springer-com.ezproxy.medma.uni-heidelberg.de/article/10.1007/s00432-017-2385-7 
|
| Verfasserangaben: | Verena S. Hoffmann, Joerg Hasford, Michael Deininger, Jorge Cortes, Michele Baccarani, Rüdiger Hehlmann |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1575540320 | ||
| 003 | DE-627 | ||
| 005 | 20220814150033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180528s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00432-017-2385-7 |2 doi | |
| 035 | |a (DE-627)1575540320 | ||
| 035 | |a (DE-576)505540320 | ||
| 035 | |a (DE-599)BSZ505540320 | ||
| 035 | |a (OCoLC)1341010008 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hoffmann, Verena Sophia |e VerfasserIn |0 (DE-588)1037222334 |0 (DE-627)755285336 |0 (DE-576)391235656 |4 aut | |
| 245 | 1 | 0 | |a Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia |c Verena S. Hoffmann, Joerg Hasford, Michael Deininger, Jorge Cortes, Michele Baccarani, Rüdiger Hehlmann |
| 264 | 1 | |c 08 March 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.05.2018 | ||
| 520 | |a Purpose: Most randomized clinical trials evaluating second generation tyrosine kinase inhibitors (TKI) for the first-line treatment of Chronic Myeloid Leukemia used as comparator the ‘standard’ dose of 400 mg imatinib daily. Several studies showed higher rates of major molecular remission (MMR) at 12 months with 800 mg compared to 400 mg, suggesting that high-dose imatinib may be the appropriate comparator rather than 400 mg. Methods: We systematically reviewed randomized trials comparing the two dosages, calculated a common estimator and compared the result to a common estimator of trials evaluating a second generation TKI in comparison with 400 mg imatinib daily. Results: We identified three trials comparing 400-800 mg imatinib resulting in a common relative risk of 1.30 (1.13-1.49) and indicating a significantly higher rate of MMR in patients treated with 800 mg imatinib (p = 0.0003). We identified five trials comparing 400 mg imatinib daily to a second generation TKI. The common relative risk for MMR at 12 months was 1.69 (1.50-1.90, p < 0.0001). Differences in the prognostic profiles precluded a direct comparison of the common efficacy estimates. Conclusions: We conclude that imatinib was probably not licensed at the optimal dose initially. We suggest that in the future, new TKIs are compared with a higher dose of imatinib. In addition, high-dose imatinib should be considered more often for routine clinical decisions based on the characteristics of the individual patient. | ||
| 700 | 1 | |a Hehlmann, Rüdiger |d 1941- |e VerfasserIn |0 (DE-588)1037003489 |0 (DE-627)751737879 |0 (DE-576)390939463 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d Berlin : Springer, 1979 |g 143(2017), 7, Seite 1311-1318 |h Online-Ressource |w (DE-627)253769515 |w (DE-600)1459285-X |w (DE-576)072578319 |x 1432-1335 |7 nnas |a Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia |
| 773 | 1 | 8 | |g volume:143 |g year:2017 |g number:7 |g pages:1311-1318 |g extent:8 |a Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-017-2385-7 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link-springer-com.ezproxy.medma.uni-heidelberg.de/article/10.1007/s00432-017-2385-7 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180528 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1037003489 |a Hehlmann, Rüdiger |m 1037003489:Hehlmann, Rüdiger |d 60000 |e 60000PH1037003489 |k 0/60000/ |p 6 |y j | ||
| 999 | |a KXP-PPN1575540320 |e 3010216513 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 28.05.2018"],"recId":"1575540320","person":[{"role":"aut","family":"Hoffmann","given":"Verena Sophia","display":"Hoffmann, Verena Sophia"},{"given":"Rüdiger","display":"Hehlmann, Rüdiger","family":"Hehlmann","role":"aut"}],"language":["eng"],"name":{"displayForm":["Verena S. Hoffmann, Joerg Hasford, Michael Deininger, Jorge Cortes, Michele Baccarani, Rüdiger Hehlmann"]},"origin":[{"dateIssuedDisp":"08 March 2017","dateIssuedKey":"2017"}],"relHost":[{"disp":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemiaJournal of cancer research and clinical oncology","type":{"bibl":"periodical","media":"Online-Ressource"},"titleAlt":[{"title":"Cancer research and clinical oncology"}],"part":{"volume":"143","year":"2017","text":"143(2017), 7, Seite 1311-1318","issue":"7","pages":"1311-1318","extent":"8"},"language":["eng","ger"],"pubHistory":["Volume 93, issue 1 (January 1979)-"],"note":["Gesehen am 19.03.25","Teils ungezählte Beil.: Supplement"],"id":{"issn":["1432-1335"],"eki":["253769515"],"zdb":["1459285-X"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Journal of cancer research and clinical oncology","subtitle":"official organ of the Deutsche Krebsgesellschaft","title_sort":"Journal of cancer research and clinical oncology"}],"origin":[{"dateIssuedDisp":"1979-","publisher":"Springer","publisherPlace":"Berlin ; Heidelberg","dateIssuedKey":"1979"}],"recId":"253769515"}],"id":{"eki":["1575540320"],"doi":["10.1007/s00432-017-2385-7"]},"physDesc":[{"extent":"8 S."}],"title":[{"title_sort":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a HOFFMANNVESYSTEMATIC0820 | ||